Gary R. Lichtenstein, M.D.
Professor of Medicine at the Hospital of the University of Pennsylvania
Director, IBD Program, Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Hospital of the University of Pennsylvania
9th Floor Penn Tower
Gastroentetrology Division Offices
One Convention Avenue
Philadelphia, PA 19104
9th Floor Penn Tower
Gastroentetrology Division Offices
One Convention Avenue
Philadelphia, PA 19104
Office: 215-349-8222
Fax: 215-349-5915
Fax: 215-349-5915
Email:
GRL@uphs.upenn.edu
GRL@uphs.upenn.edu
Publications
Education:
BA (Chemistry)
University of Pennsylvania, 1980.
MD
Mount Sinai School of Medicine, 1984.
BA (Chemistry)
University of Pennsylvania, 1980.
MD
Mount Sinai School of Medicine, 1984.
Post-Graduate Training
Intern in Medicine, Duke University Medical Center, 1984-1985.
Resident in Medicine, Duke University Medical Center, 1985-1987.
Fellow in Gastroenterology, Hospital of the University of Pennsylvania, 1987-1990.
Permanent linkIntern in Medicine, Duke University Medical Center, 1984-1985.
Resident in Medicine, Duke University Medical Center, 1985-1987.
Fellow in Gastroenterology, Hospital of the University of Pennsylvania, 1987-1990.
Description of Research Expertise
My research focuses on inflammatory bowel disease specifically Crohn's disease and Ulcerative Colitis. My particular focuses include1.) medical therapy of inflammatory bowel disease,
2.) safety of current medical therapy for IBD, and
3.) natural history of disease
Description of Clinical Expertise
Inflammatory Bowel DiseaseCrohn's Disease
Ulcerative Colitis
Selected Publications
Lichtenstein GR , Zakko S, Gordon GS, Uma Murthy4, Sedghi S, Pruitt R, Merchant K, Shaw A, Bortey E, Forbes W. : Mesalamine granules 1.5-g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: A pooled analysis from two randomized controlled trials. Alimentary Pharmacology and Therapeutics 2012.Kotlyar D, Gisbert JP, Chaparro M, Loftus EV, Blonski W, Lichtenstein GR. : Systematic Review: Duration of Exposure to Azathioprine / 6-MP As a Risk Factor for Lymphoma. Gastrenlogy 2012.
Osterman M, Lichtenstein GR. : Fistulizing Crohn’s Disease. Pediatric Inflammatory Bowel Disease, 2nd Edition. Mamula P, Markowitz JE, Baldassano R (eds.). Springer Publishers 2012.
Kotlyar D, Blonski W, Gorodenker J, Lichtenstein GR: What is the definition of corticosteroid-dependence? How do I treat patients with corticosteroid-dependent IBD? Curbside Consultation in IBD: 49 Clinical Questions. Springer Publishers (eds.). Rubin D, Friedman S, Farraye F, 2012.
Blonski W, Buchner A, Lichtenstein GR: Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease. Clinical Medicine Insights: Gastroenterology 5: 1-12, 2012.
Blonski W, Lin MV, Weiner M, Tierney A, Marchioni RM, Buchner A, Lichtenstein GR. : Cerebral Venous and Portal Vein Thrombosis in Patients With Inflammatory Bowel Disease (IBD). Gastroenterology 2012.
Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands B, Diamond RH, Blank M, Tang L. : A Pooled Analysis of Infections, Malignancy and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology 2012.
Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Blank MJ, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. : Long-Term Infliximab Maintenance Therapy for Ulcerative Colitis: the ACT 1 and 2 Extension Studies. Inflammatory Bowel Diseases 2012.
Menard Katcher P, Lichtenstein GR: Diarrhea. The Intensive Care Unit Manual, 2nd Edition Lanken PN, Hanson CW, Manaker S (eds.). WB Saunders, 2012.
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Price S, Pritchard ML, Langholff W, Londhe A, Sandborn WJ: Serious infections and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ Registry. American Journal of Gastroenterology 2012.
